CABALETTA BIO, INC. (CABA): Price and Financial Metrics
CABA Price/Volume Stats
| Current price | $16.23 | 52-week high | $19.34 |
| Prev. close | $15.99 | 52-week low | $5.11 |
| Day low | $15.35 | Volume | 983,158 |
| Day high | $16.56 | Avg. volume | 662,693 |
| 50-day MA | $15.56 | Dividend yield | N/A |
| 200-day MA | $12.52 | Market Cap | 695.44M |
CABA Stock Price Chart Interactive Chart >
CABALETTA BIO, INC. (CABA) Company Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Latest CABA News From Around the Web
Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferencePHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL. A live webcast of the presentation w |
Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business ProgressStrategic Advances in Autoimmune Disease Treatments and Financial Health |
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical development program within rheumatology and into neurology with additional IND clearances in systemic sclerosis and generalized myasthenia gravis – – CABA-201 now being evaluated in four concurrent Phase 1/2 studies, each with an initial dose of 1 x 106 cells/kg and a |
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformSOUTH SAN FRANCISCO, Calif., November 06, 2023--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, |
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-201 beyond rheumatology into neurology – – Phase 1/2 clinical trial evaluating CABA-201 in generalized myasthenia gravis features parallel cohort design and a starting dose consistent with the previously announced Phase 1/2 trials of CABA-201 for lupus, myositis a |
CABA Price Returns
| 1-mo | -5.58% |
| 3-mo | 17.10% |
| 6-mo | 33.58% |
| 1-year | 193.49% |
| 3-year | 3.64% |
| 5-year | N/A |
| YTD | 75.46% |
| 2022 | 144.06% |
| 2021 | -69.63% |
| 2020 | -10.67% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...